Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2009 07:53 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Host Conference Call to Discuss Second Quarter 2009 Results

CHARLOTTE, N.C., July 30, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release second quarter results for the period ended June 30, 2009...
July 29, 2009 08:38 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Completes $13.3 Million in Registered Direct Offering

CHARLOTTE, N.C., July 29, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it completed its previously announced registered direct offering. The final...
July 28, 2009 07:25 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Appoints William Rueckert to Board of Directors

CHARLOTTE, N.C., July 28, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that William D. Rueckert has been appointed to the Company's Board of Directors,...
July 23, 2009 08:49 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Raise $12.6 Million in Registered Direct Offering

CHARLOTTE, N.C., July 23, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has entered into definitive subscription agreements with several investors...
June 30, 2009 07:25 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Achieves Target Enrollment in Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension

* Top-line Data Expected in Q3 09 * Second Pivotal Trial On Track to Complete Enrollment in Q3 09 CHARLOTTE, N.C., June 30, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd....
June 29, 2009 16:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Added to Russell 3000 and Russell 2000 Indexes

CHARLOTTE, N.C., June 29, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it was added to the Russell 3000(r) and Russell 2000(r) Indexes when Russell...
June 11, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present Data Demonstrating Efficacy of CH-4051 in Rat Collagen-Induced Arthritis Model at EULAR 2009

CHARLOTTE, N.C., June 11, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a poster highlighting data from the Company's preclinical study of CH-4051, a...
May 21, 2009 07:25 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present Phase II Intradialytic Hypotension Data in Late Breaking Clinical Trials Session At World Congress of Nephrology 2009

CHARLOTTE, N.C., May 21, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that data from the Company's Phase II trial of Droxidopa in intradialytic hypotension...
May 06, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports First Quarter 2009 Results

CHARLOTTE, N.C., May 6, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the first quarter 2009 and presented a quarterly update on...
April 27, 2009 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Positive Results From Phase I Trial of CH-4051

CHARLOTTE, N.C., April 27, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced positive findings from its Phase I trial of CH-4051, the L-isomer of CH-1504 and...